ADAM17 and hepatocellular carcinoma: A specific inhibitor of ADAM17, ZLDI-8, sensitized HCC cells to paclitaxel in vivo and in vitro, promoted accumulation of cells arrested in G2/M phase, and inverted the EMT phenotype, confirming the advantages of the Notch signaling blockade for potentiating taxol action [485].